158 related articles for article (PubMed ID: 3027404)
1. Synergistic activation of cells by Epstein-Barr virus and B-cell growth factor.
Hutt-Fletcher LM
J Virol; 1987 Mar; 61(3):774-81. PubMed ID: 3027404
[TBL] [Abstract][Full Text] [Related]
2. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
[TBL] [Abstract][Full Text] [Related]
3. B cell activation by the nontransforming P3HR-1 substrain of the Epstein-Barr virus (EBV).
Hu CP; Aman P; Masucci MG; Klein E; Klein G
Eur J Immunol; 1986 Jul; 16(7):841-5. PubMed ID: 3013647
[TBL] [Abstract][Full Text] [Related]
4. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
Nemerow GR; McNaughton ME; Cooper NR
J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
[TBL] [Abstract][Full Text] [Related]
5. Effects of IL-4, IL-5, and IL-6 on growth and immunoglobulin production of Epstein-Barr virus-infected human B cells.
Bende RJ; Jochems GJ; Frame TH; Klein MR; van Eijk RV; van Lier RA; Zeijlemaker WP
Cell Immunol; 1992 Sep; 143(2):310-23. PubMed ID: 1324802
[TBL] [Abstract][Full Text] [Related]
6. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.
Tedder TF; Goldmacher VS; Lambert JM; Schlossman SF
J Immunol; 1986 Aug; 137(4):1387-91. PubMed ID: 3016095
[TBL] [Abstract][Full Text] [Related]
7. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-4 stimulates immunoglobulin secretion by Epstein-Barr virus (EBV)-activated tonsillar B cells, and by EBV-transformed lymphoblastoid B cell lines without increasing cell division.
Shields JG; Kotowicz K; Callard RE
Int J Clin Lab Res; 1992; 22(2):95-9. PubMed ID: 1324027
[TBL] [Abstract][Full Text] [Related]
9. In vitro transformation by Epstein-Barr virus induces a switch in growth factor and anti-IgM responsiveness in a human leukemic B cell clone.
Janssen O; Gillis S; Kabelitz D
Eur J Immunol; 1990 Jan; 20(1):7-14. PubMed ID: 2155117
[TBL] [Abstract][Full Text] [Related]
10. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
11. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2).
Nemerow GR; Houghten RA; Moore MD; Cooper NR
Cell; 1989 Feb; 56(3):369-77. PubMed ID: 2464439
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.
Moore MD; Cannon MJ; Sewall A; Finlayson M; Okimoto M; Nemerow GR
J Virol; 1991 Jul; 65(7):3559-65. PubMed ID: 1645784
[TBL] [Abstract][Full Text] [Related]
13. Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines.
Cohen JH; Fischer E; Kazatchkine MD; Lenoir GM; Lefevre-Delvincourt C; Revillard JP
Scand J Immunol; 1987 Jun; 25(6):587-98. PubMed ID: 3037684
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
15. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a human B cell line that responds to B cell growth factor but not interleukin 2.
Tseng CT; Springgate CF; Piela TH; Choi YS
J Immunol; 1987 Apr; 138(8):2554-60. PubMed ID: 3031160
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor.
Ahearn JM; Hayward SD; Hickey JC; Fearon DT
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9307-11. PubMed ID: 2848261
[TBL] [Abstract][Full Text] [Related]
18. CR2 ligands modulate human B cell activation.
Bohnsack JF; Cooper NR
J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
[TBL] [Abstract][Full Text] [Related]
19. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
[TBL] [Abstract][Full Text] [Related]
20. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
Nemerow GR; Mullen JJ; Dickson PW; Cooper NR
J Virol; 1990 Mar; 64(3):1348-52. PubMed ID: 2154612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
